We noticed you’re blocking ads

Thanks for visiting RetinaToday. Our advertisers are important supporters of this site, and content cannot be accessed if ad-blocking software is activated.

In order to avoid adverse performance issues with this site, please white list https://supplements.retinatoday.com in your ad blocker then refresh this page.

Need help? Click here for instructions.

Digital Supplement | Sponsored by Novartis Pharma AG

Retinopathy of Prematurity: Transforming Treatment Paradigms

This supplement is intended for non-promotional scientific purposes only and may contain information on products or indications currently under investigation and/or that have not been approved by the regulatory authorities.The opinions and views expressed in this supplement are those of the faculty members and do not necessarily constitute the opinions or recommendations of Novartis. The presentations were accurate at the time of presentation. Any data on competitor product(s) are based on publicly available information at the time of presentation. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the SmPC or product information approved in your local country. Permissions for all content within have been received from each copyright holder for the presentations. Separate use, adaptation, and/or translation requires application for specific use permissions from each copyright holder. All product names, trademarks and registered trademarks are property of their respective owners.

Prof. Andreas Stahl

  • University Medical Center, Greifswald, Germany
  • Financial disclosure: Consultant, Honoraria, Travel (Bayer, Novartis); Research Funds (Novartis)

Prof. Neil Marlow

  • University College London, London, United Kingdom
  • Financial disclosure: Consultant (Novartis)

Prof. Maria Ana Martinez-Castellanos

  • Association to Prevent Blindness in Mexico, Hospital “Luis Sánchez Bulnes,” I.A.P, Mexico City, Mexico
  • Financial disclosure: None acknowledged

NEXT IN THIS ISSUE